Skip Navigation

JPIDS journal policies

JPIDS journal policies
Scope of the Journal
Publication ethics
Experimental ethics
Deposition of sequence and microarray data
Clinical trials
Peer review process
Press embargos
Self-archiving policy
Drug disclaimer
Material disclaimer

SCOPE OF THE JOURNAL

The Journal of the Pediatric Infectious Diseases Society (JPIDS), the official journal of the Pediatric Infectious Diseases Society, is dedicated to perinatal, childhood, and adolescent infectious diseases. The journal is a high-quality source of original research articles, clinical trial reports, guidelines, and topical reviews ranging from bench to bedside, with particular attention to the interests and needs of the pediatric infectious diseases community.

Return to top of page.

PUBLICATION ETHICS

Authors should observe high standards with respect to publication ethics as set out by the Commission on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE). Falsification or fabrication of data, plagiarism, including duplicate publication of the authors’ own work without proper citation, and misappropriation of the work are all unacceptable practices. Any cases of ethical misconduct are treated very seriously and will be dealt with in accordance with the COPE guidelines.

Authorship

Contributors Listed in Byline
The reader of the article has the right to assume that each author listed has authoritative knowledge of the subject, and that each author contributed materially to the submission. Each author will take responsibility for his or her contribution as presented in the final manuscript and the lead (or corresponding) author will warrant that the final manuscript and authorships accurately reflect the contributions of all individuals who participated substantially in the study.

An author is considered to be someone who has made substantive intellectual contributions to one or more of the following: conception and design of the study, acquisition of data, analysis and interpretation of data, or participation in drafting or revision of the submitted article. All persons designated as authors should qualify for authorship, and all those who qualify should be listed. The corresponding author/guarantor should be prepared to explain the presence and order of all authors listed. It is not the role of editors to arbitrate conflicts related to authorship.

Acquisition of funding or general supervision of the research group alone does not qualify for authorship. Such contributors should be listed in the Acknowledgments section of the manuscript.

Group as Author
When a large, multicenter group has conducted the work, the corresponding author should clearly indicate the preferred citation and group name. Also, the group should identify the individuals who accept direct responsibility for the manuscript if publicly challenged. All members of the group who are named as authors must meet the above criteria for authorship. The other members of the group should be listed in the Acknowledgments section.

Guest and Ghost Authorships
Guest authorship of supervisors, department chairs, and mentors is discouraged. Such supervision and participation should be noted in the Acknowledgments section.
Ghost authorship by individuals such as clinical research associates at pharmaceutical companies, medical writers, marketing and public relations writers who do not meet the criteria for authorship but have made substantial contributions to the research, writing, or editing of the manuscript should be named in the Acknowledgments section. Because readers may infer their endorsement of the data and conclusions, these persons must give written permission to be acknowledged.

Manuscript Preparation
If the manufacturer of a product discussed in a submitted manuscript had a role, either directly or through a third party, in the gathering or preparation of data or in the writing of the manuscript, that information must be disclosed in the Acknowledgments section. Examples:
Manuscript preparation. Merck provided assistance with study design and data acquisition.
Manuscript preparation. Statistical analyses were done by 3M Medical Division.
Manuscript preparation. MedCommunications, Inc. (Philadelphia) provided assistance in preparing and editing the manuscript.

Originality

JPIDS does not publish articles that overlap substantially with articles already published or accepted for publication, whether in print or in the electronic media, even if the new submission contains data not included in the published or accepted work. JPIDS's policy is governed by international copyright laws, ethical conduct, and the cost-effective use of resources. Readers of primary-source periodicals trust that the material they are reading is original unless there is a statement that the article is being republished with the knowledge of the author and Editor and the permission of the original copyright holder. This policy does not preclude consideration of a report that follows a presentation at a meeting or expands preliminary findings published or presented as an abstract. A published article that the author thinks may overlap substantially with the manuscript submitted for review should be included with the submission.

By submitting your manuscript to the journal it is understood that this is an original manuscript and is unpublished work not under consideration elsewhere. Plagiarism, including duplicate publication of the author’s own work, in whole or in part without proper citation is not tolerated by the journal. Manuscripts submitted to the journal may be checked for originality using anti-plagiarism software. If an attempt at undisclosed duplicate publication is identified, the article will be rejected, the owners of the copyright will be notified, and the violation may be reported to the Publications Committee of the Pediatric Infectious Diseases Society, depending on the circumstances. If duplicate publication does occur without the express written permission of the Editor, a notice of the duplication may be published in JPIDS, and additional steps may be taken at the Editor's discretion.

Conflicts of interest

At the point of submission, each author should reveal any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated—including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organizations(s), and personal relationships. There is a potential conflict of interest when anyone involved in the publication process has a financial or other beneficial interest in the products or concepts mentioned in a submitted manuscript or in competing products that might bias his or her judgment.

As part of the online submission process, corresponding authors are required to confirm whether they or their co-authors have any conflicts of interest to declare, and to provide details of these. A footnote in the Acknowledgments section of the manuscript must include a statement either that the authors have or do not have an association that might pose a conflict of interest (e.g., pharmaceutical stock ownership, consultancy, advisory board membership, relevant patents, or research funding). The name of each contributing author and any potential conflict of interest for each author for the previous 2 years should be listed.

Examples:
Potential conflicts of interest. S.A. and K.H. are shareholders in Loke Diagnostics (Aarhus, Denmark).
Potential conflicts of interest. The author has served as consultant to and has received research grants from all of the manufacturers of the lipid formulations of amphotericin.
Potential conflicts of interest. E.H.P. has been a consultant to Fujisawa Healthcare, Inc., Gilead Sciences, Novartis, and GlaxoSmithKline and is a member of the speakers' bureaus for Pharmacia and Novartis. J.A.S. has received research funding from Bayer and Pharmacia, has been a consultant for Bayer and Pfizer, and has been on the speakers' bureau for Pfizer and Ortho McNeil.

If no potential conflict exists, the phrase "No conflict" should appear after the author's name.

If the article is accepted for publication, the disclosures will be published in the Acknowledgments section.

Return to top of page.

EXPERIMENTAL ETHICS

Animal experiments

For reporting experiments animals, the Methods section should state whether the institution's, or a national research council's guide for, or any national law on the care and use of laboratory animals was followed. (See International Committee of Medical Journal Editors [ICMJE]. Uniform Requirements for Manuscripts Submitted to Biomedical Journals. http://www.icmje.org/urm_full.pdf.)

Human subjects

When reporting on human subjects, the Methods section should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association. The name of the authorizing body should be stated in the paper. The Methods section should include a statement that the patient’s written consent was obtained and any information, including illustrations, should be as anonymized as far as possible. Patients' names, initials, or hospital numbers should not be used in the text or in illustrative material.

Return to top of page.

DEPOSITION OF SEQUENCE AND MICROARRAY DATA

Nucleotide and protein sequences

If a manuscript reports on any new nucleotide or protein sequences, these must be deposited in a publicly available database at the time of submission. Nucleotide sequences should be deposited in one of the three major collaborative databases: EMBL, GenBank, or DDBJ. New sequences and their accession numbers should be listed at the beginning of the Methods section. Protein sequences should be deposited with UniProt.

Microarray data

Authors submitting microarray data should comply with the ‘Minimal Information About a Microarray Experiment’ (MIAME) guidelines. Microarray data should also be submitted to GEO (http://www.ncbi.nlm.nih.gov/geo/) or ArrayExpress (http://www.ebi.ac.uk/arrayexpress) and to provide accession numbers by the time the paper is accepted.

Return to top of page.

CLINICAL TRIALS

Registering clinical trials

In accordance with the Clinical Trial Registration Statement from the International Committee of Medical Journal Editors (ICMJE) all clinical trials published in the journal must be registered in a public trials registry at or before the onset of participant enrolment. In common with the ICMJE, JPIDS defines a clinical trial as "any research project that prospectively assigns human subjects to intervention and concurrently assigned comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome." Studies designed for other purposes—for example, phase I trials designed to evaluate pharmacokinetics or major toxicities—are exempt. For any clinical trials commencing prior to 2008, retrospective registration will be accepted.

The registry must be accessible to the public at no charge, searchable, open to all prospective registrants, managed by a not-for-profit organization, and include all the necessary information as specified by the ICMJE. A list of recommended registries can be found on the ICMJE website. Results posted in the same clinical trials registry in which the primary registration resides will not be considered prior publication if they are presented in the form of a brief abstract (<500 words or less) or a table.

The corresponding author must provide the registry's URL and the trial's registration number at the end of the manuscript's abstract. This information will be published in the journal if the article is accepted.

Reporting clinical trials

Authors of manuscripts describing results of randomized, controlled trials, whether in Major Articles or Brief Reports, should consult guidelines recommended in the revised CONSORT statement.

Other types of studies should follow established guidelines, where available. These include STARD (Standards for the Reporting of Diagnostic accuracy studies), STROBE (Strengthening the reporting of observational studies in epidemiology), PRISMA (Transparent Reporting of Systematic Reviews and Meta-Analyses) and MOOSE (Meta-analyses of observational studies). For further information on good reporting of health research studies, please go to the EQUATOR network.

Return to top of page.

PEER REVIEW PROCESS

The Editor and an Associate Editor read all unsolicited manuscript submissions. Manuscripts are assigned to an Associate Editor and sent to outside experts for peer review. The Associate Editor, aided by the reviewers' comments, makes a recommendation to the Editor regarding the merits of the manuscript. The Editor makes a final decision to accept, reject, or request revision of the manuscript. A request for revision does not guarantee ultimate acceptance of the revised manuscript. For authors who submit papers to JPIDS after having gone through the peer-review process at Journal of Infectious Diseases and Clinical Infectious Diseases, the reviews from Journal of Infectious Diseases or Clinical Infectious Diseases may be used to make the publication decision for JPIDS or the manuscript may be sent out for additional review.

Manuscripts may also be sent out for statistical review. The average time from submission to first decision is 60 days.

Revisions

Manuscripts that are sent back to authors for revision must be returned to the editorial office by 60 days after the date of the revision request. Unless the decision letter specifically indicates otherwise, it is important not to increase the text length of the manuscript in responding to the comments. The cover letter must include a point-by-point response to the reviewers and Editors’ comments, and should indicate any additional changes made. Any alteration in authorship, including a change in order of authors, must be agreed upon by all authors, and a statement signed by all authors must be submitted to the editorial office.

Return to top of page.

PRESS EMBARGOS

Release of reports that have been accepted, but not yet published, to the media or government agencies violates JPIDS policy. Release of these reports may be warranted when they pertain to issues of urgent public importance, but they may be released only if there is express written permission from the Editor.

Return to top of page.

SELF-ARCHIVING POLICY

For information about this journal's policy, please visit our Author Self-archiving Policy page.

Return to top of page.

DRUG DISCLAIMER

The mention of trade names, commercial products or organizations, and the inclusion of advertisements in JPIDS does not imply endorsement by the Society, the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated. The editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work and clinical findings published in JPIDS. The ultimate responsibility for the use and dosage of drugs mentioned in JPIDS and in the interpretation of published material lies with the medical practitioner, and the editors and publishers cannot accept liability for damages arising from any errors or omissions in JPIDS. Please inform the editors of any errors.

Return to top of page.

MATERIAL DISCLAIMER

The opinions expressed in JPIDS are those of the authors and contributors, and do not necessarily reflect those of the Society the editors, the editorial board, Oxford University Press or the organization to which the authors are affiliated.

Return to top of page.